Your session is about to expire
← Back to Search
Pembrolizumab for T-Cell Lymphoma
Study Summary
This trial will test if pembrolizumab can shrink ENKTL before chemotherapy is given.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had pneumonitis treated with steroids or have it now.I can carry out all my self-care but cannot do heavy physical work.I have been diagnosed with HIV.I am not pregnant, will use birth control, and won't have unprotected sex during the study.My kidney, liver, heart, and lung functions meet the required levels.I haven't had active treatment for another cancer, except skin cancer or in situ carcinoma, in the last 2 years.I don't have any health issues that could affect the study's results.I am at least 18 years old.I have received a transplant from another person.I do not have active Hepatitis B or C.I have not received a live vaccine in the last 30 days.I have been diagnosed with extranodal NK/T-cell lymphoma, nasal type.My cancer has spread to my brain or its coverings.I have been treated for extranodal NK/T cell lymphoma before.I am currently on medication for an infection.
- Group 1: Early-Stage NK/T-cell Lymphoma/ENKTL (Stage I/II)
- Group 2: Early-Stage NK/T-cell Lymphoma/ENKTL (Stage III/IV)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has Pembrolizumab received official clearance by the FDA?
"Our experts at Power assigned a probability score of 2 to pembrolizumab due to the lack of efficacy data; however, there is some evidence that this medication provides safe treatment."
What maladies are usually remedied by Pembrolizumab?
"Pembrolizumab is frequently utilized to treat malignant neoplasms, but it has also been found to be a viable option for treating unresectable melanoma, cases of microsatellite instability high, and diseases that have progressed after chemotherapy."
How many participants are being enrolled in this medical trial?
"To complete the trial, 19 patients that meet the established criteria must be enrolled. Those eligible to participate can join from either Memorial Sloan Kettering Monmouth in Middletown, New jersey or Memorial Sloan Kettering Bergen in Montvale, California."
What other trials have explored the potential of Pembrolizumab?
"Pembrolizumab has been investigated since 2010, with 251 studies reaching completion. Currently, there are 961 active trials being conducted in Middletown and other cities within New jersey."
Are there any venues in North America that are actively engaging with this research?
"The 16 sites offering this medication include Memorial Sloan Kettering Monmouth in Middletown, Montvale's Memorial Sloan Kettering Bergen, and Basking Ridge's (Limited Protocol Activities) Memoral Sloan Kettering. Additionally, there are 13 other locations available across the United States of America."
Does this investigation have open enrollment for participants?
"Correct. Details available on clinicaltrials.gov demonstrate that this medical study, which was initially posted on November 9th 2018, is presently recruiting patients. It requires 19 participants from 16 centres to reach its goals."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger